Foundation year: 2011

NACE classifier: 21.20

Valid certificates:

− Zāļu ražotāja labas ražošanas prakses atbilstības sertifikāts, Sertifikāta Nr. ZVA/LV/2017/015H, izsniegta 2017. gada 18. augustā.
− Speciālā atļauja (licence) zāļu ražošanai vai importēšanai: Nr. R-48/3 izsniegta 2017. gada 15. maijā.
− Aktīvo vielu ražotāju, importētāju vai izplatītāju reģistrācijas apliecība: Nr. A18-12012017, izsniegta 2017. gada 12. janvārī.
− Speciālā atļauja (licence) slēgtā tipa aptiekas atvēršanai (darbībai): Nr. A-909/2, izsniegta 2016. gada 8. novembrī.
− Speciālā atļauja darbībām ar jonizējošā starojuma avotiem Nr.: RD 14 JL 157, spēkā no 2014. gada 7. jūlija, derīga līdz 2019. gada 6. jūlijam, ar 2018. gada 1. augusta grozījumiem.

Nuclear Medicine Centre (NMC) was developed with the purpose to introduce innovative technologies in Latvia and manufacture products with high added value, providing solution for the very significant challenge of medicine – early diagnostics of oncologic diseases.
Since 2016. gada NMC is engaged in the manufacturing and use of radiopharmaceuticals - 18F-[Fludeoxyglucose] or FDG, 18F-[F-Choline] or FCH and 68Ga-[Prostate-specific antigen11] or GaPSMA for early onco-diagnostics with positron emission tomography/computer tomography (hereinafter – PET/CT) method. Active ingredients are used for the manufacturing of finished dose pharmaceuticals (RFP) accordingly to the requirements of EU legislation – Eudralex, „The rules governing medicinal products in the EU”.
NMC scientifically technological park is involved in several nuclear medicine scientific research projects, allowing to perform clinical, medical and pharmaceutical studies with PET/CT method.

In which areas are looking for cooperation

  • Education and scientific research

Products

Fludeoxyglucose (18F) is an injectable radiopharmaceutical preparation – glucose analogue with positron-emitting radionuclide fluorine-18. [18F]FDG preferential accumulation in cells that consumes glucose more intensely allows performing various type PET diagnostics. [18F]FDG is the most commonly used PET radiopharmaceutical in onco, widely used in neurology, cardiology, infectious diseases area.
PSMA – 11 is an injectable radiopharmaceutical used for prostate-specific membrane antigen used for diagnostics of expression tumour (prostate cancer) with positron-emitting tomography method (PET), including initial diagnosis of prostate cancer, determining of tumour stage, evaluation of tumour dynamics, dynamics of possible relapse, therapy planning and efficiency evaluation etc.

Showing similar companies

By the industry in which it operates

Foundation year: 2011

NACE classifier: 21.20

Turnover in the last 5 years

Data are not able

Data are not able

Empty chart placeholder

Number of employees in total and after education in the last 5 years

Data are not able

Data are not able

Empty chart placeholder

In which areas are looking for cooperation

  • Education and scientific research

Export volume over the last 5 years

Data are not able

Data are not able

Empty chart placeholder

Investing in R&D

Data are not able

Data are not able

Empty chart placeholder

NUKLEĀRĀS MEDICĪNAS CENTRS SIA

Description about enterprise:

Nuclear Medicine Centre (NMC) was developed with the purpose to introduce innovative technologies in Latvia and manufacture products with high added value, providing solution for the very significant challenge of medicine – early diagnostics of oncologic diseases.
Since 2016. gada NMC is engaged in the manufacturing and use of radiopharmaceuticals - 18F-[Fludeoxyglucose] or FDG, 18F-[F-Choline] or FCH and 68Ga-[Prostate-specific antigen11] or GaPSMA for early onco-diagnostics with positron emission tomography/computer tomography (hereinafter – PET/CT) method. Active ingredients are used for the manufacturing of finished dose pharmaceuticals (RFP) accordingly to the requirements of EU legislation – Eudralex, „The rules governing medicinal products in the EU”.
NMC scientifically technological park is involved in several nuclear medicine scientific research projects, allowing to perform clinical, medical and pharmaceutical studies with PET/CT method.

Valid certificates:

− Zāļu ražotāja labas ražošanas prakses atbilstības sertifikāts, Sertifikāta Nr. ZVA/LV/2017/015H, izsniegta 2017. gada 18. augustā.
− Speciālā atļauja (licence) zāļu ražošanai vai importēšanai: Nr. R-48/3 izsniegta 2017. gada 15. maijā.
− Aktīvo vielu ražotāju, importētāju vai izplatītāju reģistrācijas apliecība: Nr. A18-12012017, izsniegta 2017. gada 12. janvārī.
− Speciālā atļauja (licence) slēgtā tipa aptiekas atvēršanai (darbībai): Nr. A-909/2, izsniegta 2016. gada 8. novembrī.
− Speciālā atļauja darbībām ar jonizējošā starojuma avotiem Nr.: RD 14 JL 157, spēkā no 2014. gada 7. jūlija, derīga līdz 2019. gada 6. jūlijam, ar 2018. gada 1. augusta grozījumiem.

Products

Fludeoxyglucose (18F) is an injectable radiopharmaceutical preparation – glucose analogue with positron-emitting radionuclide fluorine-18. [18F]FDG preferential accumulation in cells that consumes glucose more intensely allows performing various type PET diagnostics. [18F]FDG is the most commonly used PET radiopharmaceutical in onco, widely used in neurology, cardiology, infectious diseases area.
PSMA – 11 is an injectable radiopharmaceutical used for prostate-specific membrane antigen used for diagnostics of expression tumour (prostate cancer) with positron-emitting tomography method (PET), including initial diagnosis of prostate cancer, determining of tumour stage, evaluation of tumour dynamics, dynamics of possible relapse, therapy planning and efficiency evaluation etc.